Global IgA Nephropathy Treatment Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global IgA Nephropathy Treatment Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Currently, there are two main methods for the treatment of IgA nephropathy, one is conservative therapy and the other is immunosuppressive therapy.
IgA Nephropathy Treatment report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global IgA Nephropathy Treatment market is projected to reach US$ 50 million in 2029, increasing from US$ 15 million in 2022, with the CAGR of 19.5% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
Clearances and approval of new drugs, as well as major campaigns establishments for increasing awareness among people regarding IgA Nephropathy disease and health checkups, will have a positive impact on the market growth. For instance, US Food and Drug Administration, in September 2022, provided clearance to the Investigational New Drug (IND) Application of Eldon Pharmaceutical for assessment of tegoprubart to treat IgA Nephropathy.
Growing health consciousness coupled with high per capita disposable income is significantly contributing to the market growth. According to a nationwide study published in the Journal of the American Society of Nephrology, the incidence rate of IgA nephropathy (IgAN) is estimated to be 2-10 per 100,000 individuals a year.
The USA is at high risk for such diseases due to the growing number of chronic diseases and a sedentary lifestyle. According to the US National Institute of Diabetes and Digestive and Kidney Disease, Department of Health and Human Services, Chronic kidney disease (CKD) affects more than one in seven US Adults. As per the report by the Centers for Disease Control and Prevention (CDC) on chronic kidney disease in the United States, in 2021, there are about 37 million people affected by chronic kidney diseases.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global IgA Nephropathy Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AstraZeneca
Johnson & Johnson Private Limited
Cipla Inc.
Hikma Pharmaceuticals PLC
Zydus Cadila
LEO Pharma A/S
Fresenius Kabi AG
Accord Healthcare
Abbott
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
Alembic Pharmaceuticals Limited
Apotex Inc
Eldon Pharmaceutical
Segment by Type
Corticosteroids
Immunosuppressant
ACE and ARB Inhibitors
Hospital
Pharmacy
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the IgA Nephropathy Treatment market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of IgA Nephropathy Treatment, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the IgA Nephropathy Treatment industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of IgA Nephropathy Treatment in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, IgA Nephropathy Treatment introduction, etc. IgA Nephropathy Treatment Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of IgA Nephropathy Treatment market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
IgA Nephropathy Treatment report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global IgA Nephropathy Treatment market is projected to reach US$ 50 million in 2029, increasing from US$ 15 million in 2022, with the CAGR of 19.5% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
Clearances and approval of new drugs, as well as major campaigns establishments for increasing awareness among people regarding IgA Nephropathy disease and health checkups, will have a positive impact on the market growth. For instance, US Food and Drug Administration, in September 2022, provided clearance to the Investigational New Drug (IND) Application of Eldon Pharmaceutical for assessment of tegoprubart to treat IgA Nephropathy.
Growing health consciousness coupled with high per capita disposable income is significantly contributing to the market growth. According to a nationwide study published in the Journal of the American Society of Nephrology, the incidence rate of IgA nephropathy (IgAN) is estimated to be 2-10 per 100,000 individuals a year.
The USA is at high risk for such diseases due to the growing number of chronic diseases and a sedentary lifestyle. According to the US National Institute of Diabetes and Digestive and Kidney Disease, Department of Health and Human Services, Chronic kidney disease (CKD) affects more than one in seven US Adults. As per the report by the Centers for Disease Control and Prevention (CDC) on chronic kidney disease in the United States, in 2021, there are about 37 million people affected by chronic kidney diseases.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global IgA Nephropathy Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AstraZeneca
Johnson & Johnson Private Limited
Cipla Inc.
Hikma Pharmaceuticals PLC
Zydus Cadila
LEO Pharma A/S
Fresenius Kabi AG
Accord Healthcare
Abbott
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
Alembic Pharmaceuticals Limited
Apotex Inc
Eldon Pharmaceutical
Segment by Type
Corticosteroids
Immunosuppressant
ACE and ARB Inhibitors
Segment by Application
Hospital
Pharmacy
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the IgA Nephropathy Treatment market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of IgA Nephropathy Treatment, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the IgA Nephropathy Treatment industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of IgA Nephropathy Treatment in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, IgA Nephropathy Treatment introduction, etc. IgA Nephropathy Treatment Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of IgA Nephropathy Treatment market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices